Mostrar el registro sencillo del ítem

dc.contributor.authorCano Muñoz, Mario 
dc.contributor.authorPolo Megías, Daniel
dc.contributor.authorGavira Gallardo, José Antonio 
dc.contributor.authorRodríguez López, María J. 
dc.contributor.authorConejero Lara, Francisco 
dc.date.accessioned2022-11-07T08:26:38Z
dc.date.available2022-11-07T08:26:38Z
dc.date.issued2022-12-01
dc.identifier.citationPublished version: Mario Cano-Muñoz... [et al.]. Novel chimeric proteins mimicking SARS-CoV-2 spike epitopes with broad inhibitory activity, International Journal of Biological Macromolecules, Volume 222, Part B, 2022, Pages 2467-2478, ISSN 0141-8130, [https://doi.org/10.1016/j.ijbiomac.2022.10.031]es_ES
dc.identifier.urihttps://hdl.handle.net/10481/77788
dc.description.abstractSARS-CoV-2 spike (S) protein mediates virus attachment to the cells and fusion between viral and cell membranes. Membrane fusion is driven by mutual interaction between the highly conserved heptad-repeat regions 1 and 2 (HR1 and HR2) of the S2 subunit of the spike. For this reason, these S2 regions are interesting therapeutic targets for COVID-19. Although HR1 and HR2 have been described as transiently exposed during the fusion process, no significant antibody responses against these S2 regions have been reported. Here we designed chimeric proteins that imitate highly stable HR1 helical trimers and strongly bind to HR2. The proteins have broad inhibitory activity against WT B.1 and BA.1 viruses. Sera from COVID-19 convalescent donors showed significant levels of reactive antibodies (IgG and IgA) against the HR1 mimetic proteins, whereas these antibody responses were absent in sera from uninfected donors. Moreover, both inhibitory activity and antigenicity of the proteins correlate positively with their structural stability but not with the number of amino acid changes in their HR1 sequences, indicating a conformational and conserved nature of the involved epitopes. Our results reveal previously undetected spike epitopes that may guide the design of new robust COVID-19 vaccines and therapies.es_ES
dc.description.sponsorshipThis work was supported by grants CV20.26565 from the Consejería de Economía y Conocimiento, Junta de Andalucía (Spain), PID2019.107515RB.C21 from the Spanish State Research Agency (SRA/10.13039/501100011033), and co-funded by ERDF/ESF, “A way to make Europe”/“Investing in your future. The work performed in C.M.’s laboratory was supported by grants from ANRS (Agence Nationale de Recherches sur le SIDA et les h´epatites virales), the Investissements d’Avenir program managed by the ANR under reference ANR-10-LABX-77 and EHVA (No. 681032, Horizon 2020). Work in S.B.’s laboratory was supported by grants from the Agence Nationale de la Recherche (ANR) (ANR-11-LABX-0070_TRANSPLANTEX), the INSERM (UMR_S1109), the Institut Universitaire de France (IUF), all the University of Strasbourg (IDEX UNISTRA), the European Regional Development Fund (European Union) INTERREG V program (project no. 3.2 TRIDIAG) and MSD-Avenir grant AUTOGEN.es_ES
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectCOVID-19es_ES
dc.subjectFusion inhibitores_ES
dc.subjectVaccine es_ES
dc.titleNovel chimeric proteins mimicking SARS-CoV-2 spike epitopes with broad inhibitory activity.es_ES
dc.typejournal articlees_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/H2020/681032es_ES
dc.rights.accessRightsopen accesses_ES
dc.identifier.doi10.1016/j.ijbiomac.2022.10.031
dc.type.hasVersionSMURes_ES


Ficheros en el ítem

[PDF]
[PDF]

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Attribution-NonCommercial-NoDerivatives 4.0 Internacional